Many in UAE don’t know how to deal with asthma attacks – gulfnews.com


The National

Many in UAE don't know how to deal with asthma attacks
gulfnews.com
By Mahmood Saberi, Senior Reporter Dubai: Doctors have warned that asthma attacks are increasing every year and many parents and adults are unaware of how to handle an allergic episode. As the UAE marks World Asthma Day on Tuesday, doctors say there
Sandstorms blamed for spate of asthma casesThe National
Health experts want asthma sufferers to be better informed7DAYS
First asthma prevalence study results announcedAME Info
Zawya (registration) (press release)
all 6 news articles »

View full post on asthma – Google News

Five Prime strikes deal with GSK for asthma drug – San Francisco Business Times

Five Prime strikes deal with GSK for asthma drug
San Francisco Business Times
The collaboration will give GlaxoSmithKline exclusive access to therapeutic drugs developed by Five Prime for refractory asthma and chronic obstructive pulmonary disease. The deal will allow Five Prime to receive up to $30 million over the next four
Five Prime Therapeutics Announces Second Strategic Alliance With GlaxoSmithKlineMarketWatch (press release)

all 5 news articles »

View full post on asthma – Google News

Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1000 Genomes – Xconomy


Xconomy

Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1000 Genomes
Xconomy
The company is announcing today that it has won a new contract to analyze and compare 1000 genomes for scientists at Johns Hopkins University, who are looking for genetic variants linked to asthma in African American and African Caribbean populations.
Knome Selected as Technology Partner by Johns Hopkins for Landmark 1000 MarketWatch (press release)

all 9 news articles »

View full post on asthma – Google News

Dynavax gets $3M in reworked asthma deal with AstraZeneca – Bizjournals.com (blog)

Dynavax gets $3M in reworked asthma deal with AstraZeneca
Bizjournals.com (blog)
Dynavax Technologies Corp. will receive $3 million upfront after the Berkeley drug developer and pharmaceutical giant AstraZeneca amended a deal to accelerate a trial on a experimental asthma treatment. Dynavax (NASDAQ: DVAX) will manage the early
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for AsthmaMarketWatch (press release)

all 10 news articles »

View full post on asthma – Google News

Vectura Group Enters Exclusive with Sandoz for Asthma Treatment

Vectura Group plc (“Vectura”; LSE: VEC) today announces that it has entered into an exclusive license agreement with Sandoz, the generics division of Novartis, for the development and marketing of VR315, a combination therapy for asthma/COPD, in the rest of world (“RoW”) territory. RoW territory excludes the USA and those countries included in the existing VR315 European license with Sandoz.

Under the terms of the VR315 RoW agreement, Vectura will receive a royalty on net sales and a margin on the commercial manufacture and supply of the dry powder inhaler device used to deliver VR315 for RoW. Vectura is also eligible for milestones and advance pre-launch royalties worth up to €8m; €2.5m of which are expected to be received by 30 September 2011.

Sandoz will be solely responsible for any development work required and for obtaining marketing authorisations throughout the RoW territory, which includes Japan, Canada, South America and Australia.

Dr Chris Blackwell, Chief Executive of Vectura, commented:

VR315 has a large market opportunity in these rapidly expanding territories, where patient access to good, affordable treatments for asthma and COPD is of great importance. This agreement extends our existing relationships with Sandoz and further endorses Vectura’s respiratory expertise and GyroHaler® technology.”

Combination therapy for asthma/COPD is the biggest and fastest growing sector of the respiratory market, with annual sales currently exceeding US$11 billion. Global annual sales in territories outside Europe and the US are estimated at US$2.5billion and are continuing to grow.

Vectura exclusively licensed the European rights for VR315 to Sandoz in March 2006. In December 2007, Vectura licensed Sandoz the European rights to a second combination asthma/COPD product, VR632, delivered with the same device.

Vectura Group plc

+44 (0)1249 667700
Chris Blackwell, Chief Executive
Anne Hyland, Chief Financial Officer
Julia Wilson, Director of Investor Relations

Financial Dynamics
+44 (0)20 7831 3113
Ben Atwell

Susan Quigley
Notes for editors:
About Vectura

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura’s main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25 billion.

Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and license agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura’s formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura’s business strategy.

For further information, please visit Vectura’s website at www.vectura.com

Vectura Extends Novartis Deal For VR315 Lung Drug – Fox Business


Stockopedia

Vectura Extends Novartis Deal For VR315 Lung Drug
Fox Business
VX) for its generic asthma medicine VR315, covering markets outside Europe and North America. The deal follows hot on the heals of a US licensing agreement for the drug with an unnamed company earlier this week, and means Vectura has now licensed the
VECTURA GROUP PLC : VR315 RoW License Agreement4-traders (press release)
Vectura signs up Sandoz for asthma drug in RoW; good results for ALK Abello The Pharma Letter
Vectura agrees new licensing deal with Sandoz for asthma treatmentStockopedia

all 8 news articles »

View full post on asthma – Google News

Orion, Nycomed sign deal for Easyhaler – Pharmaceutical Business Review

Orion, Nycomed sign deal for Easyhaler
Pharmaceutical Business Review
Orion, an European R&D-based pharmaceutical and diagnostic company, has signed a deal with Nycomed to jointly market Easyhaler combination products as a treatment for asthma and chronic obstructive pulmonary disease (COPD) in some of the European
Nycomed and Orion Corporation to collaborate on Easyhaler® for asthma and COPDReuters (press release)
Nycomed and Orion to sell generic Advair and SymbicortPharma Times

all 7 news articles »

View full post on asthma – Google News

Welsh adults ignorant of how to deal with child in asthma attack – WalesOnline


BBC News

Welsh adults ignorant of how to deal with child in asthma attack
WalesOnline
MOST adults in Wales would struggle to cope when faced with a child having an asthma attack. To coincide with World Asthma Day (May 4), charity Asthma UK Cymru has released disturbing figures, which show that 89% of adults in Wales would
Call for more GP asthma trainingBBC News
Insufficient GP training in asthma putting patients' lives at riskOnMedica
Asthma deaths 'could be cut with GP training'Metro
Yorkshire Post –FemaleFirst.co.uk –European Lung Foundation
all 24 news articles »

View full post on asthma – Google News